Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-&agr; Treatments in Cancer Patients

Objective Neuropsychological changes develop in patients treated by cytokine immunotherapy with interleukin-2 (IL-2) and interferon-&agr; (IFN-&agr;). However, the time course of appearance of these effects remains unclear, and their precise nature is still incompletely characterized. The objective of this study was to assess and characterize the early cognitive changes induced by IL-2 and IFN-&agr; in cancer patients at the end of the first week of treatment and to investigate the subsequent evolution of these changes. Methods The study was conducted in 47 cancer patients who received subcutaneous IL-2, administered alone (N = 17) or with IFN-&agr; (N = 7), or IFN-&agr; alone, administered subcutaneously at low doses (N = 7) or intravenously at high doses (N = 16). An automated battery of neuropsychological tests (Cambridge Neuropsychological Test Automated Battery) was used to measure reaction time, spatial working memory, and planning tasks. Cognitive tests were performed before treatment (day 1) and after 5 days (day 5) and 1 month of treatment. Results On day 5, patients treated with IL-2 alone had impaired spatial working memory and lower accuracy of planning abilities. In contrast, patients treated with IFN-&agr; did not show any impairment in performance accuracy in these tasks but showed longer latencies in the test of reaction time. Most of these early alterations persisted at the end of the first month of treatment without any obvious sign of worsening. Conclusions These findings suggest the existence of early differential neuropsychological changes in patients treated with IL-2 and IFN-&agr;.

[1]  Barbara J. Sahakian,et al.  Computer Methods of Assessment of Cognitive Function , 2002 .

[2]  R. Dantzer,et al.  Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Dantzer,et al.  Attentional and mnemonic deficits associated with infectious disease in humans , 1999, Psychological Medicine.

[4]  Patrick Rabbitt,et al.  Test\re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues , 1998, Neuropsychologia.

[5]  P. Rabbitt,et al.  A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: Implications for theories of executive functioning and cognitive aging , 1998, Journal of the International Neuropsychological Society.

[6]  H. Anisman,et al.  An assessment of the effects of central interleukin-1β, -2, -6, and tumor necrosis factor-α administration on some behavioural, neurochemical, endocrine and immune parameters in the rat , 1998, Neuroscience.

[7]  M. B. Walker,et al.  The psychological and psychiatric effects of rIL‐2 therapy: a controlled clinical trial , 1997, Psycho-oncology.

[8]  R. Oishi,et al.  Repeated interferon-α administration inhibits dopaminergic neural activity in the mouse brain , 1997, Brain Research.

[9]  M. B. Walker,et al.  The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments. , 1996, European journal of cancer.

[10]  T. Robbins.  Dissociating executive functions of the prefrontal cortex. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[11]  Douglas Walker,et al.  Inflammation and Alzheimer's disease pathogenesis , 1996, Neurobiology of Aging.

[12]  M. Hüll,et al.  Interleukin-6-associated inflammatory processes in Alzheimer's disease: New therapeutic options , 1996, Neurobiology of Aging.

[13]  T. Merigan,et al.  Multiple cerebral lesions complicating therapy with interleukin-2 , 1996, Neurology.

[14]  R. Dolan,et al.  Neural systems engaged by planning: a PET study of the Tower of London task , 1996, Neuropsychologia.

[15]  T. Robbins,et al.  Neuorpsychiatyric applications of CANTAB , 1996 .

[16]  R. Yirmiya.  Endotoxin produces a depressive-like episode in rats , 1996, Brain Research.

[17]  Alan C. Evans,et al.  Planning and Spatial Working Memory: a Positron Emission Tomography Study in Humans , 1996, The European journal of neuroscience.

[18]  R. Quirion,et al.  Interleukin-2 as a neuroregulatory cytokine , 1995, Brain Research Reviews.

[19]  R. Dantzer,et al.  Pyrogens Specifically Disrupt the Acquisition of a Task Involving Cognitive Processing in the Rat , 1995, Brain, Behavior, and Immunity.

[20]  C. Newton,et al.  Spatial Learning Impairment in Mice Infected with Legionella pneumophila or Administered Exogenous Interleukin-1-β , 1995, Brain, Behavior, and Immunity.

[21]  M. Talpaz,et al.  Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia , 1995, Neurology.

[22]  R. Dantzer,et al.  Differential effects of IL-1ra on sickness behavior and weight loss induced by IL-1 in rats , 1995, Brain Research.

[23]  Adrian M. Owen,et al.  Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man , 1995, Neuropsychologia.

[24]  P. Rabbitt,et al.  Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. , 1994, Dementia.

[25]  R. Dantzer.  How do cytokines say hello to the brain? Neural versus humoral mediation. , 1994, European cytokine network.

[26]  R. Quirion,et al.  Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2 , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  L. Crnic,et al.  Repeated Injections of Interferon-α A/D in Balb/c Mice: Behavioral Effects , 1993, Brain, Behavior, and Immunity.

[28]  C. Marsden,et al.  Fronto-striatal cognitive deficits at different stages of Parkinson's disease. , 1992, Brain : a journal of neurology.

[29]  M. Raichle,et al.  A functional anatomical study of unipolar depression , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[30]  N. Mulder,et al.  Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Beaudet,et al.  Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain , 1991, Neuroscience.

[32]  H. Kirchner,et al.  The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies. , 1991, European journal of cancer.

[33]  M. Kluger.  Fever: Role of Pyrogens and Cryogens , 1991, Physiological reviews.

[34]  T. Robbins,et al.  Planning and spatial working memory following frontal lobe lesions in man , 1990, Neuropsychologia.

[35]  R. Quirion,et al.  Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic system , 1989, Brain Research.

[36]  D. Rubinow,et al.  The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. , 1987, Annals of internal medicine.

[37]  A P Smith,et al.  Selective effects of minor illnesses on human performance. , 1987, British journal of psychology.

[38]  E. Sorkin,et al.  Immune-neuroendocrine interactions. , 1985, Journal of immunology.

[39]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[40]  K. Pearson.  On the Criterion that a Given System of Deviations from the Probable in the Case of a Correlated System of Variables is Such that it Can be Reasonably Supposed to have Arisen from Random Sampling , 1900 .

[41]  C. Meyers.  Mood and cognitive disorders in cancer patients receiving cytokine therapy. , 1999, Advances in experimental medicine and biology.

[42]  R. Dantzer,et al.  Mechanisms of the behavioural effects of cytokines. , 1999, Advances in experimental medicine and biology.

[43]  H. Anisman,et al.  Anhedonic and anxiogenic effects of cytokine exposure. , 1999, Advances in experimental medicine and biology.

[44]  R. Dantzer,et al.  Cytokines, Stress, and Depression , 1999, Advances in Experimental Medicine and Biology.

[45]  R. Dantzer,et al.  Cytokines, stress, and depression. Conclusions and perspectives. , 1999, Advances in experimental medicine and biology.

[46]  Y. Kataoka,et al.  Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. , 1997, Brain research.

[47]  L. Crnic,et al.  Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. , 1993, Brain, behavior, and immunity.

[48]  A. Caraceni,et al.  Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. , 1993, European journal of cancer.

[49]  S Folkard,et al.  Circadian rhythms in subjective alertness and core body temperature. , 1983, Chronobiologia.

[50]  D. Karnofsky.  The clinical evaluation of chemotherapeutic agents in cancer , 1949 .